Jonathan M. Elkins

Jonathan M. Elkins

Auto-generated profile, based on publicly available information

Jonathan M. Elkins

University of Oxford

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2013 in Structure
Verified
Journal Article
Open access
MSMeera Soundararajan
Meera Soundararajan
ARAnnette K. Roos
Annette K. Roos
PSPavel Savitsky
Pavel Savitsky
PFPanagis Filippakopoulos
Panagis Filippakopoulos
AKArminja N. Kettenbach
Arminja N. Kettenbach
JEJonathan M. Elkins
Jonathan M. Elkins
Dual-specificity tyrosine-(Y)-phosphorylation-regulated kinases (DYRKs) play key roles in brain development, regulation of splicing, and apoptosis, and are potential drug targets for neurodegenerative diseases and cancer. We present crystal structures of one representative member of each DYRK subfamily: DYRK1A with an ATP-mimetic inhibitor and consensus peptide, and DYRK2 including NAPA and DH (DYRK homology) box regions. The current activation model suggests that DYRKs are Ser/Thr kinases that only autophosphorylate the second tyrosine of the activation loop YxY motif during protein translation. The structures explain the roles of this tyrosine and of the DH box in DYRK activation and provide a structural model for DYRK substrate recognition. Phosphorylation of a library of naturally occurring peptides identified substrate motifs that lack proline in the P+1 position, suggesting that DYRK1A is not a strictly proline-directed kinase. Our data also show that DYRK1A wild-type and Y321F mutant retain tyrosine autophosphorylation activity.

1 March 2016 in Structure
Verified
Journal Article
Open access
FSFiona J. Sorrell
Fiona J. Sorrell
MSMarta Szklarz
Marta Szklarz
KAKamal R. Abdul Azeez
Kamal R. Abdul Azeez
JEJon M. Elkins
Jon M. Elkins
SKStefan Knapp
Stefan Knapp
The highly diverse Numb-associated kinase (NAK) family has been linked to broad cellular functions including receptor-mediated endocytosis, Notch pathway modulation, osteoblast differentiation, and dendrite morphogenesis. Consequently, NAK kinases play a key role in a diverse range of diseases from Parkinson's and prostate cancer to HIV. Due to the plasticity of this kinase family, NAK kinases are often inhibited by approved or investigational drugs and have been associated with side effects, but they are also potential drug targets. The presence of cysteine residues in some NAK family members provides the possibility for selective targeting via covalent inhibition. Here we report the first high-resolution structures of kinases AAK1 and BIKE in complex with two drug candidates. The presented data allow a comprehensive structural characterization of the NAK kinase family and provide the basis for rational design of selective NAK inhibitors.

4 September 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
JEJonathan M. Elkins
Jonathan M. Elkins
SSStefano Santaguida
Stefano Santaguida
AMAndrea Musacchio
Andrea Musacchio
SKStefan Knapp
Stefan Knapp
We present the structure of the human Aurora B kinase domain in complex with the C-terminal Aurora-binding region of human INCENP and the Aurora kinase inhibitor VX-680. The structure unexpectedly reveals a dimeric arrangement of the Aurora B:INCENP complex, which was confirmed to exist in solution by analytical ultracentrifugation. The dimerization involves a domain swap of the activation loop, resulting in a different conformation of the DFG motif as compared to that seen in other kinase complexes with VX-680. The binding of INCENP differs significantly from that seen in the Xenopus laevis Aurora B:INCENP complex currently used as a model for structure-based design for this important oncology target.

31 October 2014 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Open access
JWJing Wang
Jing Wang
SKStefan Knapp
Stefan Knapp
NPNigel Pyne
Nigel Pyne
SPSusan Pyne
Susan Pyne
JEJonathan M. Elkins
Jonathan M. Elkins
The most potent inhibitor of Sphingosine Kinase 1 (SPHK1) so far identified is PF-543. The crystal structure of SPHK1 in complex with inhibitor PF-543 to 1.8 Å resolution reveals the inhibitor bound in a bent conformation analogous to that expected of a bound sphingosine substrate but with a rotated head group. The structural data presented will aid in the design of SPHK1 and SPHK2 inhibitors with improved properties.

30 August 2019 in Science
Verified
Journal Article
Closed access
PDF file
MAMahmood M. Alam
Mahmood M. Alam
ASAna Sanchez-Azqueta
Ana Sanchez-Azqueta
OJOmar Janha
Omar Janha
EFErika L. Flannery
Erika L. Flannery
AMAmit Mahindra
Amit Mahindra
ATAndrew B. Tobin
Andrew B. Tobin
Targeting parasite's protein kinase: Malaria elimination goals are constantly eroded by the challenge of emerging drug and insecticide resistance. Alam et al. have taken established drug targets—CLK protein kinases involved in regulation of RNA splicing—and investigated how inhibition of the parasite's enzymes blocks completion of its complex life cycle. They identified an inhibitor of the parasite's CLK protein kinase that was 100-fold less active against the most closely related human protein kinase and effective at clearing rodent malaria parasites. Not only does this compound halt the development of sexual stages but it also limits transmission to the mosquito vector of the parasite, a key requirement for malaria drugs. Science , this issue p. eaau1682

1 May 2021 in Cell Chemical Biology
Verified
Journal Article
Closed access
BBBenedict-Tilman Berger
Benedict-Tilman Berger
MAMarta Amaral
Marta Amaral
DKDaria B. Kokh
Daria B. Kokh
Ariane Nunes-AlvesAriane Nunes-Alves
Ariane Nunes-Alves
DMDjordje Musil
Djordje Musil
SKStefan Knapp
Stefan Knapp